

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.)*

CollPlant Biotechnologies Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 1.5 per share (including Ordinary Shares represented by American Depositary Shares (ADSs) at a ratio of one Ordinary Share per each ADS)

(Title of Class of Securities)

19516R107

(CUSIP Number)

Strata Trust Company Custodian FBO George Walter Loewenbaum IRA
Lilian S. Loewenbaum

c/o Lilian S. Loewenbaum
1000 Westbank Dr., Ste #2A
Austin, TX 78746

Copy to:

Jason R. Schendel
Sheppard, Mullin, Richter & Hampton LLP
379 Lytton Ave.
Palo Alto, California 94301
(650) 815-2600

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 5, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Name of Reporting Person: Strata Trust Company Custodian FBO George Walter Loewenbaum IRA
<hr/>	
2.	Check the Appropriate Box if a Member of a Group
(a)	<input type="checkbox"/>
(b)	<input checked="" type="checkbox"/>
<hr/>	
3.	SEC Use Only
<hr/>	
4.	Citizenship or Place of Organization: Texas
<hr/>	
5.	Sole Voting Power: 500,000 Ordinary Shares(1)
<hr/>	
6.	Shared Voting Power: 0
<hr/>	
7.	Sole Dispositive Power: 500,000 Ordinary Shares(1)
<hr/>	
8.	Shared Dispositive Power: 0
<hr/>	
9.	Aggregate Amount Beneficially Owned by Each Reporting Person: 500,000 Ordinary Shares(1)
<hr/>	
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>
<hr/>	
11.	Percent of Class Represented by Amount in Row (9): 7.8%(2)
<hr/>	
12.	Type of Reporting Person (See Instructions): OO
<hr/>	

(1) Consists of (a) 250,000 shares of the Issuer's ordinary shares underlying American Depositary Shares ("ADSs") issuable to the Reporting Person upon conversion of the aggregate outstanding principal under a convertible loan agreement entered into between the Issuer and the Reporting Person, and (b) 250,000 shares of the Issuer's ordinary shares underlying ADSs issuable upon exercise of an ordinary warrant that will be immediately exercisable once such ordinary warrant is issued to the Reporting Person (which will occur at the second closing date under the convertible loan agreement, as described more fully in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the SEC on September 3, 2019).

(2) Based on 5,885,353 ordinary shares of the Issuer issued and outstanding as of August 30, 2019 (which number was provided by the Issuer to the Reporting Person upon the request of the Reporting Person), plus the 500,000 shares of the Issuer's ordinary shares underlying the convertible loan agreement and ordinary warrant referred to in footnote (1) above.

1.	Name of Reporting Person: Lillian S. Loewenbaum
<hr/>	
2.	Check the Appropriate Box if a Member of a Group
(a)	<input type="checkbox"/>
(b)	<input checked="" type="checkbox"/>
<hr/>	
3.	SEC Use Only
<hr/>	
4.	Citizenship or Place of Organization: United States of America
<hr/>	
5.	Sole Voting Power: 37,500 Ordinary Shares(1)
<hr/>	
6.	Shared Voting Power: 0
<hr/>	
7.	Sole Dispositive Power: 37,500 Ordinary Shares(1)
<hr/>	
8.	Shared Dispositive Power: 0
<hr/>	
9.	Aggregate Amount Beneficially Owned by Each Reporting Person: 37,500 Ordinary Shares(1)
<hr/>	
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>
<hr/>	
11.	Percent of Class Represented by Amount in Row (9): 0.6%(2)
<hr/>	
12.	Type of Reporting Person (See Instructions): IN
<hr/>	

(1) Consists of (a) 18,750 shares of the Issuer's ordinary shares underlying American Depositary Shares ("ADSs") issuable to the Reporting Person upon conversion of the aggregate outstanding principal under a convertible loan agreement entered into between the Issuer and the Reporting Person, and (b) 18,750 shares of the Issuer's ordinary shares underlying ADSs issuable upon exercise of an ordinary warrant that will be immediately exercisable once such ordinary warrant is issued to the Reporting Person (which will occur at the second closing date under the convertible loan agreement, as described more fully in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the SEC on September 3, 2019).

(2) Based on 5,885,353 ordinary shares of the Issuer issued and outstanding as of August 30, 2019 (which number was provided by the Issuer to the Reporting Person upon the request of the Reporting Person), plus the 37,500 shares of the Issuer's ordinary shares underlying the convertible loan agreement and ordinary warrant referred to in footnote (1) above.

Item 1(a). Name of Issuer:
CollPlant Biotechnologies Ltd. (the “Issuer”)

Item 1(b). Address of Issuer’s Principal Executive Offices:
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel

Item 2(a). Name of Person(s) Filing:
This statement is filed by the individuals and entities listed below, all of whom together are referred to herein as the “Reporting Persons”.

- (i) Strata Trust Company Custodian FBO George Walter Loewenbaum IRA.
- (ii) Lillian S. Loewenbaum, an individual

Item 2(b). Address of Principal Business Office or, if none, Residence:
The address of the principal business office of each of the Reporting Persons is 1000 Westbank Dr, Ste #2A, Austin, TX 78746.

Item 2(c). Citizenship:
See Item 4 of each cover page.

Item 2(d). Title of Class of Securities:
See the cover page of this filing.

Item 2(e). CUSIP Number:
19516R107.

Item 3. **If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**
Not applicable.

Item 4. Ownership.

(a) Amount beneficially owned:
See Item 9 of each cover page.

(b) Percent of class:
See Item 11 of each cover page.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:
See Item 5 of each cover page.

(ii) Shared power to vote or to direct the vote:
See Item 6 of each cover page.

(iii) Sole power to dispose or to direct the disposition of:
See Item 7 of each cover page.

(iv) Shared power to dispose or to direct the disposition of:
See Item 8 of each cover page.

Item 5. Ownership of Five Percent or Less of a Class.

If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: September 18, 2019

Strata Trust Company Custodian FBO George Walter Loewenbaum IRA

Name: /s/ Melissa Coffman

By: Melissa Coffman, authorized signatory

Dated: September 18, 2019

Name: /s/ Lillian S. Loewenbaum

EXHIBIT INDEX

Exhibit

Exhibit A: Joint Filing Agreement.

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Ordinary Shares, par value NIS 1.5 per share (including Ordinary Shares represented by American Depositary Shares (ADSs) at a ratio of one Ordinary Share per ADS, of CollPlant Biotechnologies Ltd., and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of September 18, 2019.

Dated: September 18, 2019

Strata Trust Company Custodian FBO George Walter Loewenbaum IRA

Name: /s/ Melissa Coffman

By: Melissa Coffman, authorized signatory

Dated: September 18, 2019

Name: /s/ Lillian S. Loewenbaum